C4 Therapeutics (NasdaqGS:CCCC) FY Conference Transcript

Summary of C4 Therapeutics FY Conference Call Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing a sustainable pipeline of medicines, particularly in oncology [2][3] - The company has a validated clinical oncology portfolio, including cemsidomide, an IKZF1/3 degrader [2] Key Developments and Milestones - C4 Therapeutics completed a financing round in October 2025, providing runway through the end of 2028 [3] - The MOMENTUM Phase II study has started enrollment, with patients already dosed [4] - A Phase 1b study in combination with elranatamab is expected to start next quarter [4] - The company anticipates having registrational data from the MOMENTUM study by 2028, along with the first NDA submission [5] Cemsidomide Insights - Cemsidomide is positioned as a best-in-class IKZF1/3 degrader, with a competitive efficacy profile compared to other drugs in the same class [7][8] - The drug has shown a response rate of 36% across all doses in Phase I, with a peak response rate of 53% at the highest dose [33] - Cemsidomide has a favorable safety profile, with only 6% of patients requiring dose reductions due to treatment-related adverse events [13] Market Opportunity - The myeloma market is large and growing, with an estimated peak revenue opportunity of $2.5 billion to $4 billion by 2030 [18] - There are approximately 22,000 patients in the fourth-line setting in the U.S. and EU, with expectations for growth as newer agents move into earlier lines of treatment [16] Combination Therapy Potential - The combination of cemsidomide with elranatamab (a BCMA BiTE) is expected to enhance efficacy, potentially bringing response rates on par with CAR T therapies [17][54] - The company is also exploring combinations with other agents like carfilzomib and CD38 [60] Discovery Strategy - C4 Therapeutics is focusing on inflammation, neuroinflammation, and neurodegeneration, with plans to develop first-in-class drugs against undruggable targets [19][20] - The company has identified three validated pathways and five novel targets for future development [20][21] Regulatory Considerations - The company is preparing for Accelerated Approval by ensuring high-quality data and independent evaluation of efficacy endpoints [44][45] - The recent FDA draft guidance on MRD negativity will be integrated into the Phase III trial design [48][49] Underappreciated Aspects - Cemsidomide is viewed as a foundational asset in myeloma care, with a best-in-class potential that is not fully appreciated by investors [65][66] - The unique mechanism of action and safety profile of cemsidomide may provide significant advantages in a competitive landscape [66][67]